HBM Partners was founded in 2001 with the goal to invest in private and public emerging biopharma and other healthcare-related companies.
Business Model:
Revenue: $13.5M
Employees: 2-10
Address: Bundesplatz 1
City: Zug
State: zug
Zip: 6301
Country: CH
HBM Partners focuses on venture, growth and buy-out financings of private companies as well as investments in public companies.The HBM funds invest in entrepreneurial biopharma and other healthcare-related companies in Europe, North America, India and other Emerging Markets. Their team supports the growth of the portfolio companies through all stages of development, focusing on adding value by leveraging its experience and HBM&s;s world-wide network in the industry. Investments usually range between $5 million to $50 million.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
5/2017 | connectRN | Convertible Note | 2.5M |
6/2022 | Dren Bio | Series B | 0 |
3/2022 | Karius | Series B | - |
1/2013 | Reha Technology | Private Equity Round | 12.9M |
12/2001 | Syrrx | Venture Round | 18.5M |
8/2005 | Anadys Pharmaceuticals | Private Equity Round | 71.3M |
3/2004 | Aspreva Pharmaceuticals Corp | Series A | 57M |
12/2014 | Allena Pharmaceuticals | Series B | 0 |
7/2015 | Gynesonics | Venture Round | 43M |
10/2022 | Odyssey Therapeutics | Series B | 0 |
2/2013 | Gynesonics | Series D | 21M |
1/2018 | Gynesonics | Private Equity Round | 75M |
4/2022 | Sphingotec GmbH | Convertible Note | - |
3/2002 | Agensys | Series C | 0 |
7/2014 | Gynesonics | Debt Financing | 28.4M |
9/2021 | Fore Biotherapeutics | Series C | - |
9/2009 | Sloning BioTechnology | Venture Round | - |
11/2014 | Curetis | Series B | 0 |
5/2022 | Vascular Dynamics | Series D | - |
7/2008 | Gemin X Pharmaceuticals | Series C | 38M |
5/2015 | Symbiomix Therapeutics | Series A | 41M |
4/2020 | ITeos Therapeutics | Series B | 0 |
10/2009 | Nabriva Therapeutics | Venture Round | 0 |
10/2005 | Newron Pharmaceuticals | Series B | 8.4M |
6/2022 | Mineralys Therapeutics | Series B | 0 |
12/2005 | Asthmatx | Series C | 27M |
10/2021 | Aculys Pharma | Series A | 0 |
12/2020 | Neuron23 | Series B | 80M |
2/2013 | Odyssey Thera | Venture Round | 0 |
10/2018 | 4TEEN4 Pharmaceuticals | Venture Round | 23M |
1/2004 | Cyclacel Pharmaceuticals | Series D | 38.7M |
10/2019 | Forbius | Series C | 2.5M |
3/2015 | APR Applied Pharma Research | Venture Round | - |
4/2022 | Farmalisto | Series B | - |
8/2004 | AGY Therapeutics | Series C | 9M |
12/2017 | Hookipa Pharma | Series C | 0 |
3/2022 | Neuron23 | Series C | 0 |
6/2018 | ITeos Therapeutics | Series B | 0 |
3/2022 | Aculys Pharma | Series B | 0 |
6/2018 | Iconic Therapeutics | Venture Round | 0 |
9/2020 | Monte Rosa Therapeutics | Series B | 0 |
5/2003 | Sloning BioTechnology | Venture Round | 4.9M |
5/2021 | Numab | Series C | 110.6M |
5/2015 | i-Optics | Venture Round | 15.1M |
1/2022 | Adrenomed | Convertible Note | - |
1/2022 | Mineralys Therapeutics | Series A | - |
6/2022 | Dren Bio | Series B | 0 |
6/2022 | Mineralys Therapeutics | Series B | 0 |
5/2022 | Odyssey Therapeutics | Series B | - |
5/2022 | Vascular Dynamics | Series D | - |
4/2022 | Farmalisto | Series B | - |
4/2022 | Sphingotec GmbH | Convertible Note | - |
3/2022 | Neuron23 | Series C | 0 |
3/2022 | Aculys Pharma | Series B | 0 |
3/2022 | Karius | Series B | - |
1/2022 | Mineralys Therapeutics | Series A | - |
Name | Price |
---|
Name | Size | Announced Date |
---|